Company: TVRD
Filing Date: 2025-10-07
Form Type: S-1/A
Source: 0001104659-25-097519
Chunk: 338

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-10-07
Form: S-1/A
Chunk 338
---

The Company’s cash and cash equivalents represent potential concentrations of credit risk. The Company deposits its cash and cash equivalents in financial institutions in amounts that may exceed federally insured limits, has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

The following table presents information about the Company’s significant suppliers:

| ​        | ​ |                          ​ | ​ |    ​ | ​ |                        ​ | ​ |    ​ | ​ | ​ |                     ​ | ​ |            ​ | ​ | ​ |
| ​        | ​ | For the Three Months Ended |   |      | ​ | For the Six Months Ended |   |      | ​ | ​ |                 As of | ​ |        As of |   | ​ |
| ​        | ​ |                   June 30, |   |      | ​ |                 June 30, |   |      | ​ | ​ |              June 30, | ​ | December 31, |   | ​ |
| ​        |   |                       2025 |   | 2024 |   |                     2025 | ​ | 2024 | ​ | ​ |                  2025 |   |         2024 |   | ​ |
| ​        |   |    % of operating expenses |   |      |   |  % of operating expenses |   |      | ​ | ​ | % of accounts payable |   |              | ​ | ​ |
| Vendor A |   |                         45 | % |   68 | % |                       41 | % |   61 | % | ​ |                    14 | % |           43 | % |   |

The Company’s preclinical studies and clinical trials and testing could be adversely affected by a significant interruption in the supply chain from its significant suppliers.

Cash and Cash Equivalents

The Company considers all highly liquid investments, with an original maturity of three months or less, to be cash equivalents. Cash equivalents include amounts held in money market funds in the amount of$ 19.6million and$ 31.3million as of June 30, 2025 and December 31, 2024, respectively.

The Company recorded interest income on its cash equivalents of $ million and $ million for the three months ended June 30, 2025 and 2024, respectively, and $ million and $ million for the six months ended June 30, 2025 and